Jennison Associates Portfolio holdings
Jennison Associates, founded in 1969 and headquartered in New York City, is a global investment management firm managing over $194 billion in assets as of late 2024, specializing in active equity and fixed-income strategies. A subsidiary of PGIM, the asset management arm of Prudential Financial, Jennison serves a diverse client base—including institutions, sub-advisory clients, public plans, endowments, and corporations—with a focus on fundamental research, bottom-up portfolio construction, and high-conviction investing. Known for its equity expertise across styles, geographies, and market capitalizations, as well as investment-grade fixed-income offerings, the firm employs seasoned portfolio managers averaging 29 years of industry experience and 16 years with Jennison. With additional offices in Boston and a culture emphasizing intellectual rigor and long-term client outcomes, Jennison has built a reputation for excellence and stability in the investment management industry.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Perrigo
PRGO
|
+$672M |
| 2 |
Merck
MRK
|
+$608M |
| 3 |
ICPT
Intercept Pharmaceuticals, Inc.
ICPT
|
+$384M |
| 4 |
Las Vegas Sands
LVS
|
+$378M |
| 5 |
TFCFA
Twenty-First Century Fox, Inc. Class A
TFCFA
|
+$303M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Ralph Lauren
RL
|
+$518M |
| 2 |
eBay
EBAY
|
+$474M |
| 3 |
Estee Lauder
EL
|
+$435M |
| 4 |
Goldman Sachs
GS
|
+$323M |
| 5 |
TechnipFMC
FTI
|
+$304M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 20.03% |
| 2 | Consumer Discretionary | 13.85% |
| 3 | Communication Services | 11.23% |
| 4 | Technology | 10.46% |
| 5 | Energy | 9.31% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
476
PUT
Bristol-Myers Squibb
BMY
$133B
| $12.6M | 0.01% |
242,000
-72,200
| -23% | -$3.84M |
|
477
PUT
Ionis Pharmaceuticals
IONS
$8.6B
| $12.3M | 0.01% |
+285,000
| New | +$13.8M |
|
478
Agios Pharmaceuticals
AGIO
$1.79B
| $12.1M | 0.01% |
309,407
+2,172
| +0.7% | +$72.7K |
|
|
FLXN
479
DELISTED
Flexion Therapeutics, Inc.
FLXN
| $12M | 0.01% |
+729,799
| New | +$12.6M |
|
|
PFPT
480
DELISTED
Proofpoint, Inc.
PFPT
| $11.6M | 0.01% |
+312,002
| New | +$12.2M |
|
481
Asbury Automotive
ABG
$4.31B
| $11.4M | 0.01% |
206,910
-460,292
| -69% | -$23.5M |
|
|
GWPH
482
DELISTED
GW Pharmaceuticals Plc American Depositary Shares
GWPH
| $11.3M | 0.01% |
+190,573
| New | +$11.3M |
|
483
PUT
Alnylam Pharmaceuticals
ALNY
$27.5B
| $11.2M | 0.01% |
+166,300
| New | +$12.9M |
|
|
ATHL
484
DELISTED
ATHLON ENERGY INC COM
ATHL
| $10.3M | 0.01% |
289,351
-6,467
| -2% | -$212K |
|
485
MPLX
MPLX
$59.3B
| $9.86M | 0.01% |
201,169
-41,517
| -17% | -$1.92M |
|
|
TBI
486
Trueblue
TBI
$215M
| $9.81M | 0.01% |
335,316
+279,663
| +503% | +$7.5M |
|
487
Corcept Therapeutics
CORT
$12.4B
| $9.38M | 0.01% |
2,151,617
+6,875
| +0.3% | +$24K |
|
|
PSXP
488
DELISTED
PHILLIPS 66 PARTNERS LP
PSXP
| $9.32M | 0.01% |
191,841
+1,843
| +1% | +$78.4K |
|
|
ASPX
489
DELISTED
AUSPEX PHARMACEUTICALS INC COM STK (DE)
ASPX
| $9.23M | 0.01% |
+300,000
| New | +$8.06M |
|
|
ATMI
490
DELISTED
A T M I INC
ATMI
| $9.16M | 0.01% |
269,416
-463,465
| -63% | -$14.9M |
|
|
EQM
491
DELISTED
EQM Midstream Partners, LP
EQM
| $9.15M | 0.01% |
130,177
-15,703
| -11% | -$1.01M |
|
|
TEAR
492
DELISTED
TearLab Corporation
TEAR
| $8.92M | 0.01% |
131,967
-12,288
| -9% | -$944K |
|
|
PKY
493
DELISTED
Parkway, Inc.
PKY
| $8.32M | 0.01% |
456,078
-10,482
| -2% | -$189K |
|
494
Qualys
QLYS
$5.1B
| $8.19M | 0.01% |
322,114
+896
| +0.3% | +$24.2K |
|
|
MKTO
495
DELISTED
MARKETO INC COM STK (DE)
MKTO
| $8.12M | 0.01% |
248,552
+3,966
| +2% | +$157K |
|
496
Marcus & Millichap
MMI
$1.16B
| $7.97M | 0.01% |
446,507
+85,877
| +24% | +$1.38M |
|
|
TTPH
497
DELISTED
Tetraphase Pharmaceuticals, Inc.
TTPH
| $7.91M | 0.01% |
36,297
+122
| +0.3% | +$34K |
|
|
ANAC
498
DELISTED
ANACOR PHARMACEUTICALS INC COM
ANAC
| $7.75M | 0.01% |
387,568
+3,868
| +1% | +$75K |
|
499
Alaunos Therapeutics
TCRT
$4.59M
| $7.73M | 0.01% |
11,251
-6,916
| -38% | -$4.63M |
|
500
Hilton Worldwide
HLT
$72.1B
| $7.66M | 0.01% |
114,743
-467,302
| -80% | -$30.9M |
|
Similar funds
Jennison Associates's Q1 2014 Portfolio in Review
As of Q1 2014, Jennison Associates held 826 positions worth $105B, up 2.6% from $102B the previous quarter. Its ten largest holdings account for 18% of the portfolio.
Jennison Associates's Q1 2014 filing shows 122 new, 275 increased, 321 reduced and 94 closed positions. Its largest new stake was Perrigo: 4,257,843 shares worth $659M. The largest sale was Ralph Lauren, an estimated $518M.
By sector, the portfolio is most concentrated in Healthcare at 20% of assets, up from 18% a quarter earlier, followed by Consumer Discretionary and Communication Services.
- Jennison Associates's largest Q1 2014 buy was Perrigo: 4,257,843 shares worth $659M.
- Jennison Associates added most to Merck in Q1 2014, an estimated $608M increase.
- Jennison Associates's biggest Q1 2014 reduction was Estee Lauder, cutting an estimated $435M.
- Jennison Associates fully exited Ralph Lauren in Q1 2014, selling an estimated $518M.
- Jennison Associates's ten largest holdings make up 18% of its $105B portfolio in Q1 2014.
- Jennison Associates opened 122 new positions and closed 94 in Q1 2014.
- Jennison Associates's portfolio value rose 2.6% quarter-over-quarter to $105B.
Based on Jennison Associates's 13F filing for Q1 2014, filed 7 May 2014.